Prelude Therapeutics Incorporated (PRLD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRLD SEC filings page.
Prelude Therapeutics Incorporated (PRLD) reported $12.1M in revenue for fiscal year 2025, up 73.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Prelude remains a development-stage business: revenue is emerging, but research spending and financing needs still outweigh commercial cash generation.
Revenue rose73.4% from FY2024 to FY2025 while R&D fell20.2% , indicating that narrower losses reflected spending restraint as well as increased sales. Operating cash flow still stood at-$56.3M , so emerging revenue had not yet made operations self-funding.
The company’s economics remain development-stage: FY2025 R&D of
Balance-sheet cushion narrowed: the current ratio fell from 5.3x to 2.0x between FY2024 and FY2025. Debt-to-equity rose from 0.3x to 1.1x as liabilities increased and equity contracted, making financing structure more central to the business model.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prelude Therapeutics Incorporated's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prelude Therapeutics Incorporated held $103.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $56.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Prelude Therapeutics Incorporated scores 47/100 among other emerging companies.
Prelude Therapeutics Incorporated had 63M shares outstanding at the end of fiscal year 2025, against 55M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Prelude Therapeutics Incorporated scores 54/100 among other emerging companies.
Prelude Therapeutics Incorporated spent $94.3M on research and development in fiscal year 2025, which was 80.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Prelude Therapeutics Incorporated scores 98/100 among other emerging companies.
Prelude Therapeutics Incorporated reported revenue of $12.1M in fiscal year 2025, against $7.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Prelude Therapeutics Incorporated scores 83/100 among other emerging companies.
Prelude Therapeutics Incorporated's operations used $56.3M of cash in fiscal year 2025, against $102.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Prelude Therapeutics Incorporated scores 71/100 among other emerging companies.
Prelude Therapeutics Incorporated's cash, cash equivalents and investments came to $103.2M at the end of fiscal year 2025, against $72.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Prelude Therapeutics Incorporated scores 68/100 among other emerging companies.
Prelude Therapeutics Incorporated scores -6.26, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($292.9M) relative to total liabilities ($72.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Prelude Therapeutics Incorporated passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Prelude Therapeutics Incorporated reported a net loss of $99.5M while operations used $56.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Prelude Therapeutics Incorporated generated $5.7M in revenue in Q2 2026. Against the prior quarter it is up 24.5%.
Prelude Therapeutics Incorporated's EBITDA was -$15.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.5% from the same quarter a year earlier. Against the prior quarter it is down 9.5%.
Prelude Therapeutics Incorporated reported -$13.9M in net income in Q2 2026. This represents an increase of 55.4% from the same quarter a year earlier. Against the prior quarter it is down 34.0%.
Prelude Therapeutics Incorporated earned -$0.14 per diluted share (EPS) in Q2 2026. This represents an increase of 65.9% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.
Cash & Balance Sheet
Prelude Therapeutics Incorporated recorded an outflow of $15.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 40.3% from the same quarter a year earlier. Against the prior quarter it is up 28.2%.
Prelude Therapeutics Incorporated held $26.3M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Prelude Therapeutics Incorporated's ROE was -10.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 30.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.9 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Prelude Therapeutics Incorporated invested $16.1M in research and development in Q2 2026. This represents a decrease of 37.4% from the same quarter a year earlier. Against the prior quarter it is up 18.6%.
Prelude Therapeutics Incorporated reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
PRLD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | N/A | $6.5M+116.7% | $0 | $0 | N/A | $3.0M |
| R&D Expenses | $16.1M-37.4% | $13.6M-52.8% | N/A | $21.7M-26.3% | $25.8M-12.6% | $28.8M+5.1% | N/A | $29.5M+12.2% |
| SG&A Expenses | $5.0M-21.6% | $5.2M-10.9% | N/A | $5.2M-34.2% | $6.4M-16.3% | $5.8M-16.5% | N/A | $7.9M+11.2% |
| Operating Income | -$15.5M+52.0% | -$14.2M+59.0% | N/A | -$20.4M+40.6% | -$32.2M+13.4% | -$34.6M-0.8% | N/A | -$34.4M-3.0% |
| EBITDA | -$15.1M+52.5% | -$13.8M+59.7% | N/A | -$20.0M+41.1% | -$31.8M+13.5% | -$34.2M-0.7% | N/A | -$34.0M-2.6% |
| Net Income | -$13.9M+55.4% | -$10.4M+67.6% | N/A | -$19.7M+38.9% | -$31.2M+10.1% | -$32.1M-2.1% | N/A | -$32.3M-5.4% |
| EPS (Basic) | -$0.14+65.9% | -$0.13+69.0% | -$0.20+47.4% | -$0.26+39.5% | -$0.41+10.9% | -$0.420.0% | -$0.38+19.1% | -$0.43+4.4% |
| EPS (Diluted) | -$0.14+65.9% | -$0.13+69.0% | -$0.20+47.4% | -$0.26+39.5% | -$0.41+10.9% | -$0.420.0% | -$0.38+19.1% | -$0.43+4.4% |
| Diluted Shares (Avg) | 98M+29.5% | 83M+8.6% | N/A | 76M+0.4% | 76M+0.3% | 76M+0.3% | N/A | 76M+12.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
PRLD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $189.4M+64.8% | $119.6M-15.3% | $141.3M-19.5% | $94.8M-52.0% | $114.9M-48.8% | $141.3M-42.8% | $175.5M-36.8% | $197.2M-23.7% |
| Current Assets | $154.9M+101.5% | $84.6M-17.4% | $105.7M-22.2% | $58.3M-62.7% | $76.9M-57.9% | $102.4M-50.1% | $135.9M-42.3% | $156.4M-33.4% |
| Cash & Equivalents | $26.3M+2.2% | $21.8M-46.0% | $35.3M+182.6% | $47.5M+326.9% | $25.8M-7.5% | $40.3M+63.0% | $12.5M-50.7% | $11.1M-30.0% |
| Short-Term Investments | $125.4M+164.3% | $59.8M+1.7% | $68.0M-43.9% | $7.4M-94.8% | $47.5M-68.8% | $58.8M-66.8% | $121.1M-41.7% | $142.5M-33.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $55.6M+42.3% | $59.5M+56.1% | $72.7M+65.0% | $36.2M-11.2% | $39.1M-7.0% | $38.1M+4.7% | $44.1M+8.6% | $40.8M+101.4% |
| Current Liabilities | $38.0M+81.9% | $41.7M+110.8% | $53.0M+106.7% | $18.2M-18.2% | $20.9M-10.4% | $19.8M+12.2% | $25.6M+17.5% | $22.2M+31.6% |
| Non-Current Liabilities | $17.6M-3.2% | $17.7M-3.0% | $19.7M+6.9% | $18.0M-2.9% | $18.2M-2.7% | $18.3M-2.3% | $18.4M-1.8% | $18.6M+452.4% |
| Total Equity | $133.7M+76.3% | $60.2M-41.7% | $68.6M-47.8% | $58.5M-62.6% | $75.8M-58.4% | $103.2M-51.0% | $131.5M-44.6% | $156.4M-34.3% |
| Retained Earnings | -$707.4M-9.4% | -$693.4M-12.6% | -$683.1M-17.1% | -$666.6M-20.1% | -$646.9M-23.8% | -$615.6M-26.2% | -$583.6M-27.9% | -$554.8M-31.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PRLD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.6M+40.3% | -$21.7M+36.7% | $23.1M+211.4% | -$19.1M+30.0% | -$26.1M-13.1% | -$34.2M-7.7% | -$20.7M+12.0% | -$27.3M-6.3% |
| Depreciation & Amortization | $353K-18.5% | $391K-10.1% | $418K-14.5% | $425K+4.9% | $433K-4.2% | $435K+2.1% | $489K+47.7% | $405K+45.2% |
| Stock-Based Compensation | $2.0M-46.9% | $2.0M-47.8% | N/A | $2.4M-59.1% | $3.8M-37.5% | $3.8M-30.9% | N/A | $5.9M-11.7% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $20K-94.4% | $47K-83.7% | $53K-95.3% | $63K-89.3% |
| Free Cash Flow | -$15.6M+40.3% | -$21.7M+36.7% | $23.1M+211.2% | -$19.1M+30.1% | -$26.1M-11.4% | -$34.3M-6.9% | -$20.8M+15.8% | -$27.4M-4.1% |
| Investing Cash Flow | -$65.5M-668.6% | $8.5M-86.3% | -$60.3M-372.8% | $40.1M+273.5% | $11.5M-55.9% | $62.2M+99.2% | $22.1M+185.9% | $10.7M-28.7% |
| Financing Cash Flow | $85.8M+231845.9% | -$314K-96.3% | $24.9M+73464.7% | -$5K+96.2% | $37K-37.3% | -$160K-1042.9% | -$34K-100.1% | -$131K-248.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PRLD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -270.9% | -309.5% | N/A | -314.1% | N/A | N/A | N/A | -1145.9% |
| Net Margin | -244.1% | -226.8% | N/A | -303.5% | N/A | N/A | N/A | -1075.7% |
| Return on Equity | -10.4%+30.8pp | -17.3%+13.8pp | N/A | -33.7%-13.1pp | -41.2%-22.1pp | -31.1%-16.2pp | N/A | -20.6%-7.8pp |
| Return on Assets | -7.3%+19.8pp | -8.7%+14.0pp | N/A | -20.8%-4.5pp | -27.2%-11.7pp | -22.7%-10.0pp | N/A | -16.4%-4.5pp |
| Current Ratio | 4.07+0.4x | 2.03-3.1x | 1.99-3.3x | 3.21-3.8x | 3.68-4.2x | 5.18-6.5x | 5.30-5.5x | 7.04-6.9x |
| Debt-to-Equity | 0.42-0.1x | 0.99+0.6x | 1.06+0.7x | 0.62+0.4x | 0.52+0.3x | 0.37+0.2x | 0.34+0.2x | 0.26+0.2x |
| Asset Turnover | 0.030.0x | 0.040.0x | N/A | 0.07+0.1x | 0.00 | 0.00 | N/A | 0.02 |
| FCF Margin | -273.0% | -473.5% | N/A | -294.1% | N/A | N/A | N/A | -912.0% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated PRLD | FY2025 | $12.1M | -$99.5M | N/A | $292.9M | 70/100 |
| BeyondSpring Inc. BYSI | FY2025 | $0 | -$1.0M | N/A | $32.4M | — |
| Adicet Bio, Inc. ACET | FY2025 | N/A | -$116.8M | N/A | $60.8M | — |
| OS Therapies Incorporated OSTX | FY2025 | N/A | -$28.8M | N/A | $75.8M | — |
| Adlai Nortye Group Ltd. ANL | FY2025 | $5.0M | -$109.2M | N/A | $971.8M | 32/100 |
| MiNK Therapeutics, Inc. INKT | FY2025 | N/A | -$12.5M | N/A | $63.5M | — |
Where Prelude Therapeutics Incorporated Ranks
Frequently Asked Questions
What is Prelude Therapeutics Incorporated's annual revenue?
Prelude Therapeutics Incorporated (PRLD) reported $12.1M in total revenue for fiscal year 2025. This represents a 73.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prelude Therapeutics Incorporated's revenue growing?
Prelude Therapeutics Incorporated (PRLD) revenue grew by 73.4% year-over-year, from $7.0M to $12.1M in fiscal year 2025.
Is Prelude Therapeutics Incorporated profitable?
No, Prelude Therapeutics Incorporated (PRLD) reported a net income of -$99.5M in fiscal year 2025.
What is Prelude Therapeutics Incorporated's EBITDA?
Prelude Therapeutics Incorporated (PRLD) had EBITDA of -$102.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Prelude Therapeutics Incorporated's return on equity (ROE)?
Prelude Therapeutics Incorporated (PRLD) has a return on equity of -145.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prelude Therapeutics Incorporated's free cash flow?
Prelude Therapeutics Incorporated (PRLD) recorded an outflow of $56.4M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prelude Therapeutics Incorporated's operating cash flow?
Prelude Therapeutics Incorporated (PRLD) recorded an outflow of $56.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Prelude Therapeutics Incorporated's total assets?
Prelude Therapeutics Incorporated (PRLD) had $141.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prelude Therapeutics Incorporated's capital expenditures?
Prelude Therapeutics Incorporated (PRLD) invested $67K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prelude Therapeutics Incorporated spend on research and development?
Prelude Therapeutics Incorporated (PRLD) invested $94.3M in research and development during fiscal year 2025.
What is Prelude Therapeutics Incorporated's current ratio?
Prelude Therapeutics Incorporated (PRLD) had a current ratio of 1.99 as of fiscal year 2025, which is generally considered healthy.
What is Prelude Therapeutics Incorporated's debt-to-equity ratio?
Prelude Therapeutics Incorporated (PRLD) had a debt-to-equity ratio of 1.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prelude Therapeutics Incorporated's return on assets (ROA)?
Prelude Therapeutics Incorporated (PRLD) had a return on assets of -70.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prelude Therapeutics Incorporated's P/E ratio?
Prelude Therapeutics Incorporated (PRLD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $292.9M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Prelude Therapeutics Incorporated's price-to-sales ratio?
Prelude Therapeutics Incorporated (PRLD) trades at 24.1x sales, its market capitalization divided by revenue of $12.1M revenue, FY2025. The market capitalization is $292.9M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Prelude Therapeutics Incorporated's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Prelude Therapeutics Incorporated (PRLD) held $103.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $56.3M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Prelude Therapeutics Incorporated's Altman Z-Score?
Prelude Therapeutics Incorporated (PRLD) has an Altman Z-Score of -6.26, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Prelude Therapeutics Incorporated's Piotroski F-Score?
Prelude Therapeutics Incorporated (PRLD) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prelude Therapeutics Incorporated's earnings high quality?
Prelude Therapeutics Incorporated (PRLD) reported a net loss of $99.5M while operations used $56.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated (PRLD) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.